Abstract 867: Multi-omic characterization of tumor microenvironment evolution in LBCL across treatment lines: Insights from Atlas classification and axicabtagene ciloleucel trials
Michael Mattie(Kite (United States)), Jérôme Galon(Délégation Paris 5), Darawan Rinchai(Rockefeller University), Simone Filosto(Kite (United States)), Gayatri Tiwari, Justin A. Budka(Gilead Sciences (United Kingdom)), Régis Perbost, Jenny Kim(Gilead Sciences (Australia)), Davide Bedognetti(Sidra Medical and Research Center), Rhine R. Shen(Broad Institute), Alexia Papadopoulos(Inserm), Aurélie Auguste(Veracyte (United States)), Ioana Kloos
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k